Investigational drug · Phase 3
MB12
Also called: Proposed Pembrolizumab Biosimilar
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non Squamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "MB12"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MB12", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Squamous Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MB12" as an intervention, largest first.
- Uniform Multidrug Therapy Regimen for Leprosy PatientsPivotal-lookingCompleted
University of BrasiliaAcademic, hospital or other
NCT00669643 · 859 participants · Start Feb 2007 · Primary completion Sep 2012
Drug: PB 6 doses - Rifampicin and Dapsone; PB 6 doses - Rifampicin, Clofazimine and Dapsone and 2 more · For: Leprosy
Sites: Manaus, Brazil; Fortaleza, Brazil
- A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)Pivotal-lookingActive, not recruiting
mAbxience Research S.L.Industry
NCT06687369 · 726 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 31, 2026
Drug: MB12 (Proposed Pembrolizumab Biosimilar); EU-sourced Keytruda® and 4 more · For: Non Squamous Non Small Cell Lung Cancer
Sites: Yerevan, Armenia; Sarajevo, Bosnia and Herzegovina; Tuzla, Bosnia and Herzegovina · 173 sites in all
- Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLCPivotal-lookingStatus unknown
Laboratorio Elea Phoenix S.A.Industry
NCT05668650 · 174 participants (planned) · Start Aug 15, 2023 · Primary completion Aug 2024
Drug: Pembrolizumab; Pembrolizumab biosimilar · For: Non Small Cell Lung Cancer Metastatic
Sites: Viedma, Argentina
Newest research
PubMed records naming it or its code names, newest first.
- Ionic, Directional, and Collective Interaction Regimes in Doped B12 Clusters: An IQA Perspective.
Guevara-Vela JM, Martín Pendás Á, Rocha-Rinza T · Inorg Chem 2026
- Holotranscobalamin-based algorithm for the identification of macro-vitamin B12 in analytical hypercobalaminemia.
Fernández-Tomás P, Ruiz L, Alegre E, et al. · Clin Chim Acta 2026
- A high-quality chromosome level genome assembly of the South African indigenous Nguni goat (Capra hircus).
Mdyogolo S, Nesengani LT, Tshilate T, et al. · Sci Data 2026
- Norleucine Substitution Enhances Self-Assembly of a Lanthanide-Binding Polypeptide Coiled Coil.
Sarte DB, Villaraza AJL · J Pept Sci 2025
- Association of Altered Ratio of Maternal Folic Acid and Vitamin B12 during Pregnancy with Newborn Birth Weight, Head Circumference, and Chest Circumference.
Ramijinni RR, Mahajan A, Sapehia D, et al. · J Am Nutr Assoc 2024
- The complete genome sequence of Kineothrix sp. MB12-C1, isolated from the feces of black soldier fly larvae.
Guo W, Qiu W, Zhu J, et al. · Microbiol Resour Announc 2024
Also in development for Non Squamous Non Small Cell Lung Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- and CarboplatinPhase 21 trial
CrystalGenomics, Inc. · Non Squamous Non Small Cell Lung Cancer
- IDP-001Phase 21 trial
InduPro, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.